

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

ICB commissioned 2
 Non-ICB commissioned 4
 Not applicable 2
 ICB commissioned and approved 0 (%)
 Average days to compliance 0

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) [TA1052]	Terminated appraisal	02/04/2025	TA					N/A	Terminated appraisal
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over [TA1051]	Recommended	02/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over [TA1054]	Recommended	15/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts / tertiary providers.	NHS England
Cladribine for treating active relapsing forms of multiple sclerosis [TA1053]	Recommended	15/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [TA1057]	Recommended	16/04/2025	TA	15/07/2025	ICB			This technology is commissioned by integrated care boards. Providers are Primary care and NHS hospital trusts.	Proposed amber initiated RAG rating
Molnupiravir for treating COVID-19 [TA1056]	Recommended	16/04/2025	TA	15/07/2025	ICB			This technology is commissioned by integrated care boards. Providers are Primary care providers and NHS hospital trusts.	Proposed red RAG rating
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [TA1055]	Recommended	16/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) [TA1058]	Terminated appraisal	23/04/2025	TA					N/A	Terminated appraisal